Jefferies Financial Group Inc. Purchases New Position in Penumbra, Inc. (NYSE:PEN)

Jefferies Financial Group Inc. purchased a new stake in shares of Penumbra, Inc. (NYSE:PEN - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 3,200 shares of the company's stock, valued at approximately $760,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in PEN. Quadrant Capital Group LLC boosted its stake in shares of Penumbra by 6.6% in the 4th quarter. Quadrant Capital Group LLC now owns 632 shares of the company's stock valued at $150,000 after purchasing an additional 39 shares during the last quarter. Pallas Capital Advisors LLC raised its holdings in Penumbra by 3.8% during the fourth quarter. Pallas Capital Advisors LLC now owns 1,108 shares of the company's stock worth $263,000 after buying an additional 41 shares during the last quarter. Baker Avenue Asset Management LP raised its holdings in Penumbra by 1.6% during the fourth quarter. Baker Avenue Asset Management LP now owns 3,330 shares of the company's stock worth $791,000 after buying an additional 53 shares during the last quarter. Pacer Advisors Inc. raised its holdings in Penumbra by 1.0% during the fourth quarter. Pacer Advisors Inc. now owns 5,721 shares of the company's stock worth $1,359,000 after buying an additional 57 shares during the last quarter. Finally, CIBC Asset Management Inc grew its stake in shares of Penumbra by 5.4% in the 4th quarter. CIBC Asset Management Inc now owns 1,183 shares of the company's stock worth $281,000 after acquiring an additional 61 shares in the last quarter. 88.88% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. Wells Fargo & Company increased their price target on shares of Penumbra from $305.00 to $315.00 and gave the company an "overweight" rating in a research report on Thursday, April 24th. Stifel Nicolaus set a $318.00 target price on shares of Penumbra and gave the company a "buy" rating in a research note on Thursday, April 24th. StockNews.com raised shares of Penumbra from a "hold" rating to a "buy" rating in a research note on Thursday, April 24th. Morgan Stanley raised their target price on shares of Penumbra from $240.00 to $260.00 and gave the company an "equal weight" rating in a research note on Wednesday, February 19th. Finally, Royal Bank of Canada lifted their price target on shares of Penumbra from $315.00 to $330.00 and gave the stock an "outperform" rating in a research note on Thursday, April 24th. Three research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Penumbra currently has a consensus rating of "Moderate Buy" and a consensus price target of $302.40.

Penumbra Stock Down 2.1%

Shares of PEN stock traded down $5.82 during mid-day trading on Wednesday, hitting $275.31. 41,796 shares of the stock traded hands, compared to its average volume of 439,717. The stock has a market cap of $10.66 billion, a P/E ratio of 809.66, a P/E/G ratio of 2.83 and a beta of 0.53. The stock's fifty day moving average is $280.06 and its two-hundred day moving average is $264.41. Penumbra, Inc. has a 52-week low of $148.00 and a 52-week high of $310.00. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.01 and a quick ratio of 3.25.

Penumbra (NYSE:PEN - Get Free Report) last announced its quarterly earnings data on Wednesday, April 23rd. The company reported $0.83 EPS for the quarter, beating the consensus estimate of $0.66 by $0.17. Penumbra had a net margin of 1.17% and a return on equity of 9.74%. The firm had revenue of $324.14 million during the quarter, compared to analyst estimates of $315.72 million. During the same period last year, the firm posted $0.41 EPS. Penumbra's revenue was up 16.3% on a year-over-year basis. Equities analysts predict that Penumbra, Inc. will post 3.67 EPS for the current year.

Insider Activity at Penumbra

In related news, Director Bridget O'rourke sold 100 shares of the business's stock in a transaction dated Thursday, May 15th. The shares were sold at an average price of $286.15, for a total value of $28,615.00. Following the sale, the director now directly owns 5,423 shares in the company, valued at approximately $1,551,791.45. The trade was a 1.81% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Thomas Wilder sold 360 shares of the business's stock in a transaction dated Monday, March 31st. The shares were sold at an average price of $264.58, for a total transaction of $95,248.80. Following the completion of the sale, the director now owns 4,533 shares in the company, valued at approximately $1,199,341.14. This trade represents a 7.36% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 176,696 shares of company stock valued at $50,207,745. 4.20% of the stock is owned by company insiders.

Penumbra Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.